Efficacy and safety of traditional Chinese medicine and antiviral antibody therapies for COVID-19: a network meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

SUN Yanjun ¹ , SONG Shuang ¹ , ZHANG Ludan ¹ , LI Nan ¹ , GAO Shengwei ¹ , ZHANG Li ³ , XING Yongfa ³ , MU Wei ³ , WANG Baohe ² ,  HUANG Yuhong ³

1. Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P. R. China;
2. The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300073, P. R. China;
3. The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, P. R. China;

Corresponding?author：

HUANG Yuhong, Email: hyh101@126.com

Keywords：

Traditional Chinese medicine; Antiviral antibody; COVID-19; Efficacy; Safety; Network meta-analysis

DOI：

10.7507/1672-2531.202207008

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy and safety of traditional Chinese medicine (TCM) and antiviral antibody therapy in the treatment of COVID-19. Methods PubMed, EMbase, The Cochrane Library, Web of Science, CNKI, WanFang Data, VIP and SinoMED databases were electronically searched to collect randomized controlled trials (RCTs) on efficacy and safety of traditional Chinese medicine and antiviral antibody therapies for COVID-19 from inception to June 2022. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies; then, network meta-analysis was performed by using Stata 14.0 software. Results A total of 44 RCTs were included. The results of network meta-analysis showed that, for mortality rate, the rank of cumulative probability was: TCM+ standard care (SC) (100%)>convalescent plasma (CP)+SC (42%)>SC (8%). In terms of hospital stay time, the rank of cumulative probability was: TCM+SC (95.5%)>SC (31.4%)>CP+SC (23.2%). In terms of time to viral clearance, the rank of cumulative probability was: TCM+SC (97.4%)>SC (37.4%)>CP+SC (15.2%). In the aspect of mechanical ventilation rate, the rank of cumulative probability was: TCM+SC (98.9%)>CP+SC (42.9%)>SC (8.3%). In the aspect of adverse reactions/events, the rank of cumulative probability was: TCM+SC (99.9%)>SC (47.9%)>CP+SC (2.2%). Conclusion The current evidence shows that TCM combined with SC is the most effective treatment in reducing mortality, shortening hospitalization time and viral negative conversion time, reducing mechanical ventilation rate, and the incidence of adverse reactions/events is low. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify above conclusion.

Citation： SUN Yanjun, SONG Shuang, ZHANG Ludan, LI Nan, GAO Shengwei, ZHANG Li, XING Yongfa, MU Wei, WANG Baohe, HUANG Yuhong. Efficacy and safety of traditional Chinese medicine and antiviral antibody therapies for COVID-19: a network meta-analysis. Chinese Journal of Evidence-Based Medicine, 2022, 22(11): 1309-1318. doi: 10.7507/1672-2531.202207008 Copy

1.	Johns Hopkins University. Coronavirus resource center. Available at: https://coronavirus.jhu.edu/map.html.
2.	National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Available at: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf.
3.	Zhao Z, Li Y, Zhou L, et al. Prevention and treatment of COVID-19 using Traditional Chinese medicine: a review. Phytomedicine, 2021, 85: 153308.
4.	Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol, 2021, 21(6): 382-393.
5.	Zhang S, Yang Z, Chen ZL, et al. Efficacy and safety of "three Chinese patent medicines and three TCM prescriptions" for COVID-19: a systematic review and network meta-analysis. Evid Based Complement Alternat Med, 2022, 2022: 4654793.
6.	Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ, 2021, 374: n2231.
7.	Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med, 2017, 12(1): 103-111.
8.	國家衛生健康委辦公廳, 國家中醫藥管理局辦公室. 新型冠狀病毒肺炎診療方案(試行第九版). Available at: http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88/files/ef09aa4070244620b010951b088b8a27.pdf.
9.	The U. S. Food and drug administration. Drugs and non-vaccine biological Products. Available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs.
10.	European Medicines Agency. COVID-19 treatments. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-treatments.
11.	Higgins J, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1. 0. The Cochrane Collaboration, 2013.
12.	Ma Q, Xie Y, Wang Z, et al. Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2. J Ethnopharmacol, 2021, 279: 114367.
13.	Zhao J, Yang X, Wang C, et al. Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a. Biomed Pharmacother, 2020, 129: 110436.
14.	Wenguang X, Chanjuan Z, Jixian Z, et al. Randomized controlled study of a diagnosis and treatment plan for moderate coronavirus disease 2019 that integrates Traditional Chinese and Western Medicine. J Tradit Chin Med, 2022, 42(2): 234-241.
15.	Zeng C, Yuan Z, Zhu J, et al. Therapeutic effects of traditional Chinese medicine (Maxingshigan-Weijing Decoction) on COVID-19: An open-label randomized controlled trial. Integr Med Res, 2021, 10(Suppl): 100782.
16.	Zhou S, Feng J, Xie Q, et al. Traditional Chinese medicine shenhuang granule in patients with severe/critical COVID-19: A randomized controlled multicenter trial. Phytomedicine, 2021, 89: 153612.
17.	Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine, 2021, 93: 153775.
18.	Wang JB, Wang ZX, Jing J, et al. Exploring an integrative therapy for treating COVID-19: a randomized controlled trial. Chin J Integr Med, 2020, 26(9): 648-655.
19.	Zhang L, Wu L, Xu X, et al. Efficacy and safety of lianhua qingke tablets in the treatment of mild and common-type COVID-19: a randomized, controlled, multicenter clinical study. Evid Based Complement Alternat Med, 2022, 2022: 8733598.
20.	Zhang XY, Lv L, Zhou YL, et al. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: a multicenter, prospective, open-label and randomized controlled trial. Phytother Res, 2021, 35(8): 4401-4410.
21.	Xu X, Zhang J, Zheng W, et al. Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study. Ann Palliat Med, 2021, 10(5): 5146-5155.
22.	Liu J, Yang W, Liu Y, et al. Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): a single-center, open-label, randomized controlled trial. Phytomedicine, 2021, 91: 153671.
23.	Zhao C, Li L, Yang W, et al. Chinese medicine formula Huashibaidu granule early treatment for mild COVID-19 patients: an unblinded, cluster-randomized clinical trial. Front Med (Lausanne), 2021, 8: 696976.
24.	葉玲, 趙紅佳, 徐順貴, 等. 加味升降散治療普通型COVID-19的臨床效果研究. 中外醫學研究, 2021, 19(28): 9-13.
25.	平祥華, 徐海齡, 付東方, 等. 加味玉屏風散聯合西藥治療COVID-19的臨床觀察. 基層醫學論壇, 2021, 25(2): 149-151.
26.	段璨, 夏文廣, 鄭嬋娟, 等. 金花清感顆粒聯合西醫常規治療方案治療輕型新型冠狀病毒肺炎的臨床觀察. 中醫雜志, 2020, 61(17): 1473-1477.
27.	張又莉, 雷亮, 徐勇, 等. 金銀花口服液治療新型冠狀病毒肺炎80例臨床療效分析. 中國藥業, 2020, 29(9): 23-26.
28.	劉武, 蘇曉勇, 廖祥莉, 等. 抗病毒藥物聯合中藥治療輕型新型冠狀病毒肺炎的效果分析. 當代醫藥論叢, 2021, 19(2): 159-160.
29.	陳超武, 李曉良, 劉亞峰, 等. 連花清瘟膠囊治療新型冠狀病毒肺炎臨床研究. 中西醫結合研究, 2021, 13(1): 1-4.
30.	余平, 李葉子, 萬少兵, 等. 連花清瘟顆粒聯合阿比多爾治療輕度新型冠狀病毒肺炎的療效觀察. 中國藥學雜志, 2020, 55(12): 1042-1045.
31.	王月, 陳立, 鄭玲, 等. 清肺排毒湯聯合常規治療對新冠肺炎患者的臨床療效. 中成藥, 2021, 43(3): 656-659.
32.	王林, 徐夢, 王瑜, 等. 生脈散合參苓白術散加減治療普通型2019冠狀病毒病臨床研究. 中華中醫藥雜志, 2020, 35(8): 4268-4271.
33.	顏成果, 閃海霞, 裴旭東, 等. 疏風解毒膠囊聯合α-干擾素和阿比多爾治療普通型新型冠狀病毒肺炎的療效和安全性分析. 廣州中醫藥大學學報, 2022, 39(3): 475-480.
34.	陳良忠, 劉輝, 肖國龍. 血必凈注射液在新冠肺炎治療中的療效及對CRP的影響. 中國處方藥, 2020, 18(10): 110-111.
35.	鄭子洲, 白志剛, 李常杰, 等. 中醫辨證治療新型冠狀病毒肺炎效果觀察. 交通醫學, 2020, 34(2): 117-118.
36.	廖國榮. 自擬中藥湯劑在新型冠狀肺炎患者中的應用效果及安全性研究. 國際感染病學(電子版), 2020, 9(2): 353.
37.	Kirenga B, Byakika-Kibwika P, Muttamba W, et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ Open Respir Res, 2021, 8(1): e001017.
38.	Gharbharan A, Jordans CCE, GeurtsvanKessel C, et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun, 2021, 12(1): 3189.
39.	Devos T, Van Thillo Q, Compernolle V, et al. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur Respir J, 2022, 59(2): 2101724.
40.	AlQahtani M, Abdulrahman A, Almadani A, et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Sci Rep, 2021, 11(1): 9927.
41.	Bar KJ, Shaw PA, Choi GH, et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest, 2021, 131(24): e155114.
42.	K?rper S, Weiss M, Zickler D, et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest, 2021, 131(20): e152264.
43.	Pouladzadeh M, Safdarian M, Eshghi P, et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Intern Emerg Med, 2021, 16(8): 2181-2191.
44.	Menichetti F, Popoli P, Puopolo M, et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Netw Open, 2021, 4(11): e2136246.
45.	Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA, 2020, 324(5): 460-470.
46.	Avenda?o-Solá C, Ramos-Martínez A, Mu?ez-Rubio E, et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest, 2021, 131(20): e152740.
47.	Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase Ⅱ multicentre randomised controlled trial (PLACID Trial). BMJ, 2020, 371: m3939.
48.	Bajpai M, Maheshwari A, Dogra V, et al. Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-Ⅱ trial). BMJ Open, 2022, 12(4): e055189.
49.	Bégin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med, 2021, 27(11): 2012-2024.
50.	Sekine L, Arns B, Fabro BR, et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur Respir J, 2022, 59(2): 2101471.
51.	Holm K, Lundgren MN, Kjeldsen-Kragh J, et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden. BMC Res Notes, 2021, 14(1): 440.
52.	林菲菲, 黃建平, 楊軍, 等. 宣肺清熱方輔助治療普通型新型冠狀病毒肺炎臨床研究. 浙江中西醫結合雜志, 2020, 30(12): 977-981.
53.	李亞冬, 張文靜. 新冠肺炎中西醫治療方案臨床效果評價. 光明中醫, 2020, 35(9): 1273-1275.
54.	艾香英, 羅純, 林路平, 等. 廣州市新型冠狀病毒肺炎中西醫結合治療療效. 中國熱帶醫學, 2020, 20(8): 746-750.
55.	傅曉霞, 林路平, 譚行華. 中西醫結合治療新型冠狀病毒肺炎37例臨床研究. 中藥新藥與臨床藥理, 2020, 31(5): 600-604.
56.	Wu SS, Zhou QX, Zeng XY, et al. Comparative effectiveness and safety of 32 pharmacological interventions recommended by guidelines for coronavirus disease 2019: a systematic review and network meta-analysis combining 66 trials. Chin Med J (Engl), 2021, 134(16): 1920-1929.
57.	Yu R, Zhang S, Zhao D, et al. A systematic review of outcomes in COVID-19 patients treated with western medicine in combination with traditional Chinese medicine versus western medicine alone. Expert Rev Mol Med, 2022, 24: e5.
58.	Li L, Xie H, Wang L, et al. The efficacy and safety of combined chinese herbal medicine and western medicine therapy for COVID-19: a systematic review and meta-analysis. Chin Med, 2022, 17(1): 77.
59.	Jiang F, Xu N, Zhou Y, et al. Contribution of traditional Chinese medicine combined with conventional western medicine treatment for the novel coronavirus disease (COVID-19), current evidence with systematic review and meta-analysis. Phytother Res, 2021, 35(11): 5992-6009.
60.	Wang H, Xu B, Zhang Y, et al. Efficacy and safety of traditional Chinese medicine in coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Front Pharmacol, 2021, 12: 609213.
61.	Farhangnia P, Dehrouyeh S, Safdarian AR, et al. Recent advances in passive immunotherapies for COVID-19: the evidence-based approaches and clinical trials. Int Immunopharmacol, 2022, 109: 108786.
62.	Chan W, He B, Wang X, et al. Pandemic COVID-19: Current status and challenges of antiviral therapies. Genes Dis, 2020, 7(4): 502-519.
63.	Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev, 2020, (7): CD013600.
64.	Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. BMJ, 2020, 370: m3379.
65.	Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med, 2021, 384(7): 619-629.
66.	Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early convalescent plasma for high-risk outpatients with COVID-19. N Engl J Med, 2021, 385(21): 1951-1960.

1. Johns Hopkins University. Coronavirus resource center. Available at: https://coronavirus.jhu.edu/map.html.
2. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Available at: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf.
3. Zhao Z, Li Y, Zhou L, et al. Prevention and treatment of COVID-19 using Traditional Chinese medicine: a review. Phytomedicine, 2021, 85: 153308.
4. Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol, 2021, 21(6): 382-393.
5. Zhang S, Yang Z, Chen ZL, et al. Efficacy and safety of "three Chinese patent medicines and three TCM prescriptions" for COVID-19: a systematic review and network meta-analysis. Evid Based Complement Alternat Med, 2022, 2022: 4654793.
6. Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ, 2021, 374: n2231.
7. Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med, 2017, 12(1): 103-111.
8. 國家衛生健康委辦公廳, 國家中醫藥管理局辦公室. 新型冠狀病毒肺炎診療方案(試行第九版). Available at: http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88/files/ef09aa4070244620b010951b088b8a27.pdf.
9. The U. S. Food and drug administration. Drugs and non-vaccine biological Products. Available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs.
10. European Medicines Agency. COVID-19 treatments. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-treatments.
11. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1. 0. The Cochrane Collaboration, 2013.
12. Ma Q, Xie Y, Wang Z, et al. Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2. J Ethnopharmacol, 2021, 279: 114367.
13. Zhao J, Yang X, Wang C, et al. Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a. Biomed Pharmacother, 2020, 129: 110436.
14. Wenguang X, Chanjuan Z, Jixian Z, et al. Randomized controlled study of a diagnosis and treatment plan for moderate coronavirus disease 2019 that integrates Traditional Chinese and Western Medicine. J Tradit Chin Med, 2022, 42(2): 234-241.
15. Zeng C, Yuan Z, Zhu J, et al. Therapeutic effects of traditional Chinese medicine (Maxingshigan-Weijing Decoction) on COVID-19: An open-label randomized controlled trial. Integr Med Res, 2021, 10(Suppl): 100782.
16. Zhou S, Feng J, Xie Q, et al. Traditional Chinese medicine shenhuang granule in patients with severe/critical COVID-19: A randomized controlled multicenter trial. Phytomedicine, 2021, 89: 153612.
17. Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine, 2021, 93: 153775.
18. Wang JB, Wang ZX, Jing J, et al. Exploring an integrative therapy for treating COVID-19: a randomized controlled trial. Chin J Integr Med, 2020, 26(9): 648-655.
19. Zhang L, Wu L, Xu X, et al. Efficacy and safety of lianhua qingke tablets in the treatment of mild and common-type COVID-19: a randomized, controlled, multicenter clinical study. Evid Based Complement Alternat Med, 2022, 2022: 8733598.
20. Zhang XY, Lv L, Zhou YL, et al. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: a multicenter, prospective, open-label and randomized controlled trial. Phytother Res, 2021, 35(8): 4401-4410.
21. Xu X, Zhang J, Zheng W, et al. Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study. Ann Palliat Med, 2021, 10(5): 5146-5155.
22. Liu J, Yang W, Liu Y, et al. Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): a single-center, open-label, randomized controlled trial. Phytomedicine, 2021, 91: 153671.
23. Zhao C, Li L, Yang W, et al. Chinese medicine formula Huashibaidu granule early treatment for mild COVID-19 patients: an unblinded, cluster-randomized clinical trial. Front Med (Lausanne), 2021, 8: 696976.
24. 葉玲, 趙紅佳, 徐順貴, 等. 加味升降散治療普通型COVID-19的臨床效果研究. 中外醫學研究, 2021, 19(28): 9-13.
25. 平祥華, 徐海齡, 付東方, 等. 加味玉屏風散聯合西藥治療COVID-19的臨床觀察. 基層醫學論壇, 2021, 25(2): 149-151.
26. 段璨, 夏文廣, 鄭嬋娟, 等. 金花清感顆粒聯合西醫常規治療方案治療輕型新型冠狀病毒肺炎的臨床觀察. 中醫雜志, 2020, 61(17): 1473-1477.
27. 張又莉, 雷亮, 徐勇, 等. 金銀花口服液治療新型冠狀病毒肺炎80例臨床療效分析. 中國藥業, 2020, 29(9): 23-26.
28. 劉武, 蘇曉勇, 廖祥莉, 等. 抗病毒藥物聯合中藥治療輕型新型冠狀病毒肺炎的效果分析. 當代醫藥論叢, 2021, 19(2): 159-160.
29. 陳超武, 李曉良, 劉亞峰, 等. 連花清瘟膠囊治療新型冠狀病毒肺炎臨床研究. 中西醫結合研究, 2021, 13(1): 1-4.
30. 余平, 李葉子, 萬少兵, 等. 連花清瘟顆粒聯合阿比多爾治療輕度新型冠狀病毒肺炎的療效觀察. 中國藥學雜志, 2020, 55(12): 1042-1045.
31. 王月, 陳立, 鄭玲, 等. 清肺排毒湯聯合常規治療對新冠肺炎患者的臨床療效. 中成藥, 2021, 43(3): 656-659.
32. 王林, 徐夢, 王瑜, 等. 生脈散合參苓白術散加減治療普通型2019冠狀病毒病臨床研究. 中華中醫藥雜志, 2020, 35(8): 4268-4271.
33. 顏成果, 閃海霞, 裴旭東, 等. 疏風解毒膠囊聯合α-干擾素和阿比多爾治療普通型新型冠狀病毒肺炎的療效和安全性分析. 廣州中醫藥大學學報, 2022, 39(3): 475-480.
34. 陳良忠, 劉輝, 肖國龍. 血必凈注射液在新冠肺炎治療中的療效及對CRP的影響. 中國處方藥, 2020, 18(10): 110-111.
35. 鄭子洲, 白志剛, 李常杰, 等. 中醫辨證治療新型冠狀病毒肺炎效果觀察. 交通醫學, 2020, 34(2): 117-118.
36. 廖國榮. 自擬中藥湯劑在新型冠狀肺炎患者中的應用效果及安全性研究. 國際感染病學(電子版), 2020, 9(2): 353.
37. Kirenga B, Byakika-Kibwika P, Muttamba W, et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ Open Respir Res, 2021, 8(1): e001017.
38. Gharbharan A, Jordans CCE, GeurtsvanKessel C, et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun, 2021, 12(1): 3189.
39. Devos T, Van Thillo Q, Compernolle V, et al. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur Respir J, 2022, 59(2): 2101724.
40. AlQahtani M, Abdulrahman A, Almadani A, et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Sci Rep, 2021, 11(1): 9927.
41. Bar KJ, Shaw PA, Choi GH, et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest, 2021, 131(24): e155114.
42. K?rper S, Weiss M, Zickler D, et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest, 2021, 131(20): e152264.
43. Pouladzadeh M, Safdarian M, Eshghi P, et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Intern Emerg Med, 2021, 16(8): 2181-2191.
44. Menichetti F, Popoli P, Puopolo M, et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Netw Open, 2021, 4(11): e2136246.
45. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA, 2020, 324(5): 460-470.
46. Avenda?o-Solá C, Ramos-Martínez A, Mu?ez-Rubio E, et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest, 2021, 131(20): e152740.
47. Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase Ⅱ multicentre randomised controlled trial (PLACID Trial). BMJ, 2020, 371: m3939.
48. Bajpai M, Maheshwari A, Dogra V, et al. Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-Ⅱ trial). BMJ Open, 2022, 12(4): e055189.
49. Bégin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med, 2021, 27(11): 2012-2024.
50. Sekine L, Arns B, Fabro BR, et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur Respir J, 2022, 59(2): 2101471.
51. Holm K, Lundgren MN, Kjeldsen-Kragh J, et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden. BMC Res Notes, 2021, 14(1): 440.
52. 林菲菲, 黃建平, 楊軍, 等. 宣肺清熱方輔助治療普通型新型冠狀病毒肺炎臨床研究. 浙江中西醫結合雜志, 2020, 30(12): 977-981.
53. 李亞冬, 張文靜. 新冠肺炎中西醫治療方案臨床效果評價. 光明中醫, 2020, 35(9): 1273-1275.
54. 艾香英, 羅純, 林路平, 等. 廣州市新型冠狀病毒肺炎中西醫結合治療療效. 中國熱帶醫學, 2020, 20(8): 746-750.
55. 傅曉霞, 林路平, 譚行華. 中西醫結合治療新型冠狀病毒肺炎37例臨床研究. 中藥新藥與臨床藥理, 2020, 31(5): 600-604.
56. Wu SS, Zhou QX, Zeng XY, et al. Comparative effectiveness and safety of 32 pharmacological interventions recommended by guidelines for coronavirus disease 2019: a systematic review and network meta-analysis combining 66 trials. Chin Med J (Engl), 2021, 134(16): 1920-1929.
57. Yu R, Zhang S, Zhao D, et al. A systematic review of outcomes in COVID-19 patients treated with western medicine in combination with traditional Chinese medicine versus western medicine alone. Expert Rev Mol Med, 2022, 24: e5.
58. Li L, Xie H, Wang L, et al. The efficacy and safety of combined chinese herbal medicine and western medicine therapy for COVID-19: a systematic review and meta-analysis. Chin Med, 2022, 17(1): 77.
59. Jiang F, Xu N, Zhou Y, et al. Contribution of traditional Chinese medicine combined with conventional western medicine treatment for the novel coronavirus disease (COVID-19), current evidence with systematic review and meta-analysis. Phytother Res, 2021, 35(11): 5992-6009.
60. Wang H, Xu B, Zhang Y, et al. Efficacy and safety of traditional Chinese medicine in coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Front Pharmacol, 2021, 12: 609213.
61. Farhangnia P, Dehrouyeh S, Safdarian AR, et al. Recent advances in passive immunotherapies for COVID-19: the evidence-based approaches and clinical trials. Int Immunopharmacol, 2022, 109: 108786.
62. Chan W, He B, Wang X, et al. Pandemic COVID-19: Current status and challenges of antiviral therapies. Genes Dis, 2020, 7(4): 502-519.
63. Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev, 2020, (7): CD013600.
64. Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. BMJ, 2020, 370: m3379.
65. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med, 2021, 384(7): 619-629.
66. Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early convalescent plasma for high-risk outpatients with COVID-19. N Engl J Med, 2021, 385(21): 1951-1960.

Chinese Journal of Evidence-Based Medicine

Efficacy and safety of traditional Chinese medicine and antiviral antibody therapies for COVID-19: a network meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content